Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?

Scott A MacDiarmid1

  • 1Clinical Faculty, Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. smacdiarmid@tucpa.com

BJU International
|May 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management.

International journal of clinical practice·2020
Same author

A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome.

Urology·2019
Same author

A pilot feasibility study of treating overactive bladder patients with percutaneous saphenous nerve stimulation.

Neurourology and urodynamics·2018
Same author

Posterior tibial nerve stimulation before a trial of sacral nerve stimulation for refractory urge incontinence.

The Journal of urology·2014
Same author

Effect of baseline symptom severity on continence improvement mediated by oxybutynin chloride topical gel.

Open access journal of urology·2013
Same author

Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.

The Journal of urology·2012

Urinary incontinence impacts many adults, with overactive bladder (OAB) treatments like muscarinic antagonists offering symptom relief. Newer delivery systems, such as the oxybutynin transdermal patch, aim to improve treatment effectiveness and reduce side effects.

Area of Science:

  • Urology
  • Pharmacology
  • Geriatrics

Background:

  • Urinary incontinence affects a significant portion of the US adult and elderly population.
  • It substantially impacts quality of life, comparable to other chronic diseases.
  • Overactive bladder (OAB) is a common condition managed by muscarinic receptor antagonists.

Purpose of the Study:

  • To review the efficacy and side-effect profiles of OAB treatments.
  • To highlight strategies for improving the therapeutic index of OAB medications.
  • To evaluate the role of novel drug delivery systems in OAB management.

Main Methods:

  • Review of current therapeutic strategies for OAB.
  • Comparison of efficacy and side-effect profiles of various muscarinic antagonists.

Related Experiment Videos

  • Analysis of newer formulations, including transdermal systems.

    • Main Results:

    • Muscarinic receptor antagonists demonstrate 65-75% efficacy in reducing OAB symptoms.
    • The oxybutynin transdermal system shows a lower incidence of dry mouth compared to oral formulations.
    • Transdermal delivery bypasses first-pass metabolism, potentially reducing side effects.

    Conclusions:

    • Anticholinergic agents remain crucial for OAB management.
    • Novel drug delivery systems and targeted therapies are enhancing the therapeutic index for OAB.
    • The oxybutynin transdermal patch is a promising option for elderly patients due to its favorable side-effect profile and low drug interaction potential.